Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).
1 finding from 1 review
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).
1 finding from 1 review
Pain ( · people with telangiectasias and reticular veins
Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in pain ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).
1 finding from 1 review
Recurrence · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reduction in physical signs Decrease in seizure frequency End of treatment · people with conversion disorder according to DSM‐IV or ICD‐10 criteria
1 finding from 1 review
Level of functioning · people with conversion disorder according to DSM‐IV or ICD‐10 criteria
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life As measured by QOLIE10 (lower is better) · people with conversion disorder according to DSM‐IV or ICD‐10 criteria
1 finding from 1 review
Adverse events · people with conversion disorder according to DSM‐IV or ICD‐10 criteria
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 3 to 17 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life measurements · children aged 3 to 17 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · children aged 3 to 17 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resolution of daytime urinary incontinence · children aged 3 to 17 years with daytime urinary incontinence
It is very uncertain whether pelvic floor muscle training (PFMT) with urotherapy changes resolution of daytime urinary incontinence after 12 months of… compared with urotherapy alone (very low certainty).
1 finding from 1 review
Frequency of incontinence episodes · children aged 3 to 17 years with daytime urinary incontinence
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Objective measurement of volume of incontinent episodes · children aged 3 to 17 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment success as defined by the authors · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain frequency and intensity (measured as part of the 0‐500 point IBS‐SSS questionnaire) · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review